| |
|
|
|
|
|
|
|||
|
Blood, 16 April 2009, Vol. 113, No. 16, pp. 3726-3734. Prepublished online as a Blood First Edition Paper on September 12, 2008; DOI 10.1182/blood-2008-04-146928.
IMMUNOBIOLOGY In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein1 Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD; 2 Section on Genomic Structure and Function, Laboratory of Molecular and Cellular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 3 Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Batiment Lwoff, Institut Pasteur, Paris, France; and 4 Department of Microbiology, Molecular Genetics, and Immunology, University of Kansas Medical Center, Kansas City
The human T-cell leukemia/lymphoma virus type 1 (HTLV-1) ORF-I encodes a 99–amino acid hydrophobic membrane protein, p12I, that affects receptors in different cellular compartments. We report here that proteolytic cleavage dictates different cellular localization and functions of p12I. The removal of a noncanonical endoplasmic reticulum (ER) retention/retrieval signal within the amino terminus of p12I is necessary for trafficking to the Golgi apparatus and generation of a completely cleaved 8-kDa protein. The 8-kDa protein in turn traffics to the cell surface, is recruited to the immunologic synapse following T-cell receptor (TCR) ligation, and down-regulates TCR proximal signaling. The uncleaved 12-kDa form of p12I resides in the ER and interacts with the β and
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||